Market Intelligence, Clinical Progress, and High-Purity Reagents for DLBCL and B-Cell Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD79B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD79B ECD-Fc Fusion Protein Extracellular domain (Met1-Ala158), HEK293 expressed, Human IgG1 Fc tag. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. |
View CD79B Products |
| Gene Delivery | CD79B Lentivirus Particles Full-length ORF with native transmembrane domain for stable B-cell line construction. Titer >1×10^8 TU/mL. |
View CD79B Products |
| Benchmark Ab | Anti-CD79B (Sequence of Polatuzumab) Recombinant human IgG1 positive control. Sequence Verified. |
View CD79B Products |
| Validator | CD79B siRNA Set Three target-specific sequences for knockdown verification. RNase-free, validated by qPCR. |
View CD79B Products |
| Related Target A | CD79A (Ig-alpha) Heterodimeric partner of CD79B; structural homology screening essential for specificity. |
View CD79A Products |
| Related Target B | CD20 (MS4A1) Pan-B-cell marker; combination therapy standard (R-CHP); resistance bypass analysis. |
View CD20 Products |
| Related Target C | BTK Downstream kinase in BCR signaling pathway; combination resistance strategy. |
View BTK Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval (Toxicology requirement) | Human/Cynomolgus/Rhesus CD79B ECD-Fc proteins available with >95% purity; sequence identity verified by mass spec |
| CD79A homolog counter-screening | CD79A and CD79B homolog panel proteins strictly verified by mass spec; ensure epitope specificity |
| ADC Internalization efficiency | High-purity (>95%) CD79B ECD-Fc preserves native conformation for accurate binding kinetics; suitable for internalization assays |
| Lack of Controls | Clinical Benchmark Antibodies (Polatuzumab biosimilar sequence) included for assay normalization |
| False Positives | Validated siRNA included for specificity checks; confirm on-target toxicity vs off-target effects |
Live CD79B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD79B therapeutics has matured with the approval of Polatuzumab vedotin (Polivy), establishing ADCs as the validated modality for DLBCL. Current R&D is shifting toward next-generation ADCs with optimized payloads (exatecan, PBD dimers) and combination strategies (Polivy + R-CHP) to replace standard chemoimmunotherapy. As first-generation therapies reach blockbuster status, the next wave targets resistance mechanisms involving BCR pathway rewiring and CD79B mutation variants.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Approved) | Roche/Genentech (Polivy) | DLBCL, FL (1L/2L) | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| ADC (Pipeline) | ADC Therapeutics, BioNTech | Relapsed/Refractory B-NHL | Cyno cross-reactivity panel (Toxicology requirement) |
| Bispecific | Regeneron, Teneobio | Autoimmune (SLE) | Heterodimer validation (Need CD79A/B co-expression systems) |
| CAR-T | Academic institutions | R/R DLBCL | Cell surface density assays (Need lentivirus stable lines) |
| Small Molecule / BTK combo | AstraZeneca, BeiGene | Refractory DLBCL | Pathway Selectivity Assay (Need CD79B mutants vs WT proteins) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Affinity: For hematological ADC, moderate-to-high affinity (low nM to pM) facilitates rapid binding and internalization, but excessive affinity may cause "binding site barrier" in solid tumors (though DLBCL is diffuse).
- Internalization Efficiency: Core mechanism of action for ADC; antibodies must recognize non-blocking or mildly blocking epitopes to maintain BCR surface expression for sustained internalization.
- Epitope Specificity: Must exclude cross-reactivity with CD79A (Ig-alpha) via counter-screening with CD79A homolog panel.
- Cross-Species Reactivity: Since Polatuzumab does not bind murine CD79B, preclinical toxicology relies on cynomolgus monkey models; human/cyno cross-reactivity validation is critical for IND.
Recommended Screening Assays
| Screening Goal | Recommended Assay | TarMart Product Support |
|---|---|---|
| Affinity & Kinetics | SPR / BLI (using CD79B ECD-Fc immobilized) | HEK293-expressed CD79B ECD-Fc, >95% purity, MW confirmed by mass spec |
| Internalization Efficiency | pH-sensitive dye (pHrodo) or FACS internalization assay | CD79B full-length lentivirus stable cell lines (Raji/CHO background) |
| Cross-Species Reactivity | Human/cyno/mouse ortholog binding ELISA / SPR | Human/cyno/mouse CD79B ECD-Fc ortholog protein set, sequence verified |
| Specificity Counter-Screen | Anti-CD79A, anti-CD20 isotype protein panel | CD79A homolog protein (>95% purity) for strict binding discrimination |
| Resistance Mutation Screening | Mutant vs WT protein differential SPR/ELISA | CD79B mutant recombinant proteins (e.g., ITAM region mutants) for resistance mechanism studies |
| Functional Validation | siRNA knockdown followed by binding loss assay | CD79B siRNA set for specificity control in FACS and cell binding assays |
Related Target Recommendations
Based on BCR signaling pathway and B-cell biology, the following cross-selling opportunities are recommended:
- CD79A (Ig-alpha): Heterodimeric partner of CD79B; essential for BCR surface expression. Customers often require CD79A protein for co-IP, BRET, or dual-positive cell line construction.
- CD20 (MS4A1): Standard-of-care target for B-cell lymphoma; CD79B ADC is frequently combined with CD20 monoclonal antibodies. Cross-sell CD20 antigen, Obinutuzumab/Rituximab biosimilar, and combination assay kits.
- BTK: Downstream kinase in BCR signaling; BTK inhibitor resistance is linked to CD79B mutations. Provide BTK recombinant protein and inhibitor screening tools to complete the pathway research platform.